Backed ParcelBio, which secured $13M in financing for next-generation mRNA medicine development.
MAY 2026
ParcelBio is focused on developing a new class of mRNA medicines that enhance protein expression and durability, targeting autoimmune diseases, oncology, and therapeutic proteins through their proprietary APEXm™ platform
ParcelBio is focused on developing a new class of mRNA medicines that enhance protein expression and durability, targeting autoimmune diseases, oncology, and therapeutic proteins through their proprietary APEXm™ platform.